Reset filter
Keywords
Lung Neoplasms ×
Show more Keywords
Table of contents
  1. 1. Clinical Trial
  2. 2. Routine Documentation
  3. 3. Registry/Cohort Study
  4. 4. Quality Assurance
  5. 5. Data Standard
  6. 6. Patient-Reported Outcome
  7. 7. Medical Specialty
    1. 7.1. Anesthesiology
    1. 7.2. Dermatology
    1. 7.3. ENT
    1. 7.4. Geriatrics
    1. 7.5. Gynecology/Obstetrics
    1. 7.6. Internal Medicine
      1. Hematology
      1. Infectious Diseases
      1. Cardiology/Angiology
      1. Pneumology
      1. Gastroenterology
      1. Nephrology
      1. Endocrinology/Metabolic Diseases
      1. Rheumatology
    1. 7.7. Neurology
    1. 7.8. Ophthalmology
    1. 7.9. Palliative Care
    1. 7.10. Pathology/Forensics
    1. 7.11. Pediatrics
    1. 7.12. Psychiatry/Psychosomatics
    1. 7.13. Radiology
    1. 7.14. Surgery
      1. General/Visceral Surgery
      1. Neurosurgery
      1. Plastic Surgery
      1. Thoracic Surgery
      1. Trauma/Orthopedics
      1. Vascular Surgery
    1. 7.15. Urology
    1. 7.16. Dental Medicine/OMS
Selected data models

You must log in to select data models for download or further analysis.

34 Search results.
Relevance Rating New first Old first

dbGaP phs000942 Use of WGS for Diagnosis and Discovery in the Cancer Genetics Clinic - Eligibility

- 11/27/24 - 5 forms, 1 itemgroup, 1 item, 1 language
Itemgroup: IG.elig
Principal Investigator: Theodora S. Ross, MD, PhD, Department of Internal Medicine, UT Southwestern Medical Center, Dallas, TX, USA, and Department of Cancer Genetics, UT Southwestern Medical Center, Dallas, TX, USA MeSH: Neoplasms,Breast Neoplasms,Ovarian Neoplasms,Peritoneal Neoplasms,Skin Neoplasms,Esophageal Neoplasms,Thyroid Neoplasms,Urinary Bladder Neoplasms,Endometrial Neoplasms,Fallopian Tube Neoplasms,Melanoma,Testicular Neoplasms,Bile Duct Neoplasms,Lung Neoplasms,Colonic Neoplasms,Adrenocortical Carcinoma,Carcinoma, Renal Cell,Colonic Polyps,Adenomatous Polyposis Coli,Lymphoma, Large B-Cell, Diffuse,Pheochromocytoma,Paraganglioma,Leiomyoma,Hemangioblastoma,Hyperparathyroidism,Pancreatic Neoplasms,Vulvar Neoplasms,Brain Neoplasms,Liver Neoplasms,Kidney Neoplasms,Prostatic Neoplasms,Glioblastoma,Oncocytoma, renal https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000942 Despite the potential of whole-genome sequencing (WGS) to improve patient diagnosis and care, the empirical value of WGS in the cancer genetics clinic is unknown. We performed WGS on members of two cohorts of cancer genetics patients: those with BRCA1/2 mutations (n = 176) and those without (n = 82). Initial analysis of potentially pathogenic variants (PPVs, defined as nonsynonymous variants with allele frequency 1% in ESP6500) in 163 clinically-relevant genes suggested that WGS will provide useful clinical results. This is despite the fact that a majority of PPVs were novel missense variants likely to be classified as variants of unknown significance (VUS). Furthermore, previously reported pathogenic missense variants did not always associate with their predicted diseases in our patients. This suggests that the clinical use of WGS will require large-scale efforts to consolidate WGS and patient data to improve accuracy of interpretation of rare variants. While loss-of-function (LoF) variants represented only a small fraction of PPVs, WGS identified additional cancer risk LoF PPVs in patients with known BRCA1/2 mutations and led to cancer risk diagnoses in 21% of non-BRCA cancer genetics patients after expanding our analysis to 3209 ClinVar genes. These data illustrate how WGS can be used to improve our ability to discover patients' cancer genetic risks. "Reprinted from doi:10.1016/j.ebiom.2014.12.003, with permission from EBioMedicine."

pht004834.v1.p1

1 itemgroup 5 items

pht004835.v1.p1

1 itemgroup 5 items

pht004836.v1.p1

1 itemgroup 16 items

pht004837.v1.p1

1 itemgroup 5 items

Lung Cancer NCT00096265 Quality of Life - QF RTOG Phase III-Multiple Brain Mets - 2277089v3.0 - QF RTOG Phase III-Multiple Brain Mets

- 1/9/15 - 1 form, 3 itemgroups, 15 items, 1 language
Itemgroups: Header, Module 1, Module 2
QF RTOG Phase III-Multiple Brain Mets Radiation Therapy and Stereotactic Radiosurgery With or Without Temozolomide or Erlotinib in Treating Patients With Brain Metastases Secondary to Non-Small Cell Lung Cancer Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=D7FA4A0B-63F5-6417-E034-0003BA12F5E7

Eligibility Lung Neoplasm NCT00469066

- 8/6/17 - 1 form, 2 itemgroups, 18 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Cone Beam CT Scanning in Lung and Bladder Cancer.; ODM derived from: https://clinicaltrials.gov/show/NCT00469066

Lung Cancer NCT00096265 Quality of Life - PQ RTOG Phase III Multiple Brain Metastases Fact Subscale - 2277326v3.0 - PQ RTOG Phase III Multiple Brain Metastases Fact Subscale

- 9/27/21 - 1 form, 3 itemgroups, 43 items, 1 language
Itemgroups: Header, Physical Well-Being, Additional Concerns
PQ RTOG Phase III Multiple Brain Metastases Fact Subscale Radiation Therapy and Stereotactic Radiosurgery With or Without Temozolomide or Erlotinib in Treating Patients With Brain Metastases Secondary to Non-Small Cell Lung Cancer Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=D7FA7BFE-292F-6626-E034-0003BA12F5E7

Lung Cancer NCT00096265 Quality of Life - PF RTOG Phase III Multiple Brain Metastases Fact General - 2277123v3.0 - PF RTOG Phase III Multiple Brain Metastases Fact General

- 1/9/15 - 1 form, 5 itemgroups, 36 items, 1 language
Itemgroups: Header, Physical Well-Being, Social/Family Well-Being, Emotional Well-Being, Functional Well-Being
PF RTOG Phase III Multiple Brain Metastases Fact General Radiation Therapy and Stereotactic Radiosurgery With or Without Temozolomide or Erlotinib in Treating Patients With Brain Metastases Secondary to Non-Small Cell Lung Cancer Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=D7FA4FF6-6FF6-643F-E034-0003BA12F5E7

Lung Cancer NCT00096265 Treatment - TF RTOG Phase III - Multiple Brain Mets Treatment Summary Form - 2277910v3.0 - TF RTOG Phase III - Multiple Brain Mets Treatment Summary Form

- 1/9/15 - 1 form, 1 itemgroup, 74 items, 1 language
Itemgroup: Header
TF RTOG Phase III - Multiple Brain Mets Treatment Summary Form Radiation Therapy and Stereotactic Radiosurgery With or Without Temozolomide or Erlotinib in Treating Patients With Brain Metastases Secondary to Non-Small Cell Lung Cancer Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=D81D1978-6B15-04EC-E034-0003BA12F5E7

Lung Cancer NCT00096265 On-Study - I1 RTOG Phase III - Multiple Brain Mets Initial Evaluation Form - 2277804v3.0 - I1 RTOG Phase III - Multiple Brain Mets Initial Evaluation Form

- 1/9/15 - 1 form, 5 itemgroups, 29 items, 1 language
Itemgroups: Header, Module 1, Patient Characteristics, Size of Lesion(s), Module 4
I1 RTOG Phase III - Multiple Brain Mets Initial Evaluation Form Radiation Therapy and Stereotactic Radiosurgery With or Without Temozolomide or Erlotinib in Treating Patients With Brain Metastases Secondary to Non-Small Cell Lung Cancer Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=D81B6746-376F-61E1-E034-0003BA12F5E7

Lung Cancer NCT00096265 Toxicity - AE RTOG Phase III Multiple Brain Metastases Adverse Event Evaluation Form - 2277984v3.0 - AE RTOG Phase III Multiple Brain Metastases Adverse Event Evaluation Form

- 1/9/15 - 1 form, 1 itemgroup, 65 items, 1 language
Itemgroup: Header
AE RTOG Phase III Multiple Brain Metastases Adverse Event Evaluation Form Radiation Therapy and Stereotactic Radiosurgery With or Without Temozolomide or Erlotinib in Treating Patients With Brain Metastases Secondary to Non-Small Cell Lung Cancer Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=D81D6073-C669-0831-E034-0003BA12F5E7

Lung Cancer NCT00096265 Follow-Up - F1 RTOG Phase III - Multiple Brain Mets Follow-Up Form - 2278053v3.0 - F1 RTOG Phase III - Multiple Brain Mets Follow-Up Form

- 1/9/15 - 1 form, 1 itemgroup, 51 items, 1 language
Itemgroup: Header
F1 RTOG Phase III - Multiple Brain Mets Follow-Up Form Radiation Therapy and Stereotactic Radiosurgery With or Without Temozolomide or Erlotinib in Treating Patients With Brain Metastases Secondary to Non-Small Cell Lung Cancer Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=D81E0CAD-FB8C-12F8-E034-0003BA12F5E7

Lung Cancer NCT00096265 Quality of Life - Cover Sheet RTOG Phase III-Multiple Brain Mets Quality of Life Cover Sheet - 2277042v3.0 - Cover Sheet RTOG Phase III-Multiple Brain Mets Quality of Life Cover Sheet

- 1/9/15 - 1 form, 4 itemgroups, 22 items, 1 language
Itemgroups: Header, Module 1, Module 2, Module 3
Cover Sheet RTOG Phase III-Multiple Brain Mets Quality of Life Cover Sheet Radiation Therapy and Stereotactic Radiosurgery With or Without Temozolomide or Erlotinib in Treating Patients With Brain Metastases Secondary to Non-Small Cell Lung Cancer Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=D7FA3BB6-3594-636D-E034-0003BA12F5E7

Lung Cancer NCT00096265 Treatment - T1 RTOG GBM-EBXRT & RT Phase III - Multiple Brain Mets Radiotherapy Summary Form - 2277868v3.0 - T1 RTOG GBM-EBXRT & RT Phase III - Multiple Brain Mets Radiotherapy Summary Form

- 1/9/15 - 1 form, 4 itemgroups, 26 items, 1 language
Itemgroups: Header, Module 1, Dose Summary, Module 3
T1 RTOG GBM-EBXRT & RT Phase III - Multiple Brain Mets Radiotherapy Summary Form Radiation Therapy and Stereotactic Radiosurgery With or Without Temozolomide or Erlotinib in Treating Patients With Brain Metastases Secondary to Non-Small Cell Lung Cancer Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=D81A9D08-29A3-641E-E034-0003BA12F5E7

Eligibility Lung Cancer NCT00955695

- 7/7/20 - 1 form, 1 itemgroup, 20 items, 1 language
Itemgroup: Criteria
Radiation Therapy to the Brain or Observation in Preventing Brain Metastases in Patients With Advanced Non-Small Cell Lung Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT00955695

Contact

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial